乙型肝炎表面抗原水平可用于排除乙型肝炎的肝硬化 e 抗原

StephenW

乙型肝炎表面抗原水平可用于排除乙型肝炎的肝硬化 e 抗原阳性慢性乙型肝炎：SONIC-B 研究的结果
Milan J Sonneveld、Bettina E Hansen、Willem P Brouwer、Henry L-Y Chan、Teerha Piratvisuth、Ji-Dong Jia、Stefan Zeuzem、Rong-Nan Chien、Robert J de Knegt、Cynthia Wat ... 显示更多
《传染病杂志》，第 225 卷，第 11 期，2022 年 6 月 1 日，第 1967-1973 页，https://doi.org/10.1093/infdis/jiaa192
发表：
2020 年 4 月 21 日
文章历史

    pdfPDF
    拆分视图
    引用
    权限图标权限
    分享

抽象的
背景

血清乙型肝炎表面抗原 (HBsAg) 水平与慢性乙型肝炎病毒 (HBV) 感染的持续时间相关，并可预测肝纤维化的程度。
方法

我们分析了来自 SONIC-B 数据库的数据，该数据库包含来自 8 个全球随机试验和 2 个大型肝病中心的数据。探讨了 HBsAg 水平与存在显着纤维化 (Ishak 3-4) 或肝硬化 (Ishak 5-6) 之间的关系，并确定了临床相关的临界值以排除肝硬化。
结果

数据集包括 2779 名患者：1866 名乙型肝炎 e 抗原 (HBeAg) 阳性； 322 肝硬化。在 HBeAg 阳性患者中，较低的 HBsAg 水平与较高的显着纤维化发生率（优势比 [OR]，0.419；P < .001）和肝硬化（OR，0.435；P < .001）相关。 HBeAg 阴性患者之间未观察到相关性。在 HBeAg 阳性患者中，基因型特异性 HBsAg 临界值具有出色的阴性预测值 (>97%) 和低误分类率 (≤7.1%)，因此可能有助于排除肝硬化。 HBsAg 临界值的诊断性能在不能用纤维化 4 (FIB-4) 排除肝硬化的患者中具有可比性。
结论

乙型肝炎病毒基因型特异性 HBsAg 截止值可能有助于排除基因型 B、C 和 D 的 HBeAg 阳性患者存在肝硬化，并且可以作为 FIB-4 的辅助手段，以减少进一步检测的需要。
肝硬化、纤维化、乙型肝炎、HBsAg
话题：

    肝硬化 纤维化 乙型肝炎抗原 基因型 乙型肝炎 e抗原 乙型肝炎表面抗原 乙型肝炎，慢性乙型肝炎病毒

StephenW

Hepatitis B Surface Antigen Levels Can Be Used to Rule Out Cirrhosis in Hepatitis B e Antigen-Positive Chronic Hepatitis B: Results From the SONIC-B Study
Milan J Sonneveld, Bettina E Hansen, Willem P Brouwer, Henry L-Y Chan, Teerha Piratvisuth, Ji-Dong Jia, Stefan Zeuzem, Rong-Nan Chien, Robert J de Knegt, Cynthia Wat ... Show more
The Journal of Infectious Diseases, Volume 225, Issue 11, 1 June 2022, Pages 1967–1973, https://doi.org/10.1093/infdis/jiaa192
Published:
21 April 2020
Article history

    pdfPDF
    Split View
    Cite
    Permissions Icon Permissions
    Share

Abstract
Background

Serum hepatitis B surface antigen (HBsAg) levels correlate with the duration of chronic hepatitis B virus (HBV) infection and may predict the extent of hepatic fibrosis.
Methods

We analyzed data from the SONIC-B database, which contains data from 8 global randomized trials and 2 large hepatology centers. Relationship between HBsAg levels and presence of significant fibrosis (Ishak 3–4) or cirrhosis (Ishak 5–6) were explored, and clinically relevant cutoffs were identified to rule out cirrhosis.
Results

The dataset included 2779 patients: 1866 hepatitis B e antigen (HBeAg)-positive; 322 with cirrhosis. Among HBeAg-positive patients, lower HBsAg levels were associated with higher rates of significant fibrosis (odds ratio [OR], 0.419; P < .001) and cirrhosis (OR, 0.435; P < .001). No relationship was observed among HBeAg-negative patients. Among HBeAg-positive patients, genotype-specific HBsAg cutoffs had excellent negative predictive values (>97%) and low misclassification rates (≤7.1%) and may therefore have utility in ruling out cirrhosis. Diagnostic performance of the HBsAg cutoffs was comparable among patients in whom cirrhosis could not be ruled out with fibrosis 4 (FIB-4).
Conclusions

Hepatitis B virus genotype-specific HBsAg cutoffs may have utility in ruling out presence of cirrhosis in HBeAg-positive patients with genotypes B, C, and D and can be an adjunct to FIB-4 to reduce the need for further testing.
cirrhosis, fibrosis, hepatitis B, HBsAg
Topic:

    liver cirrhosis fibrosis hepatitis b antigens genotype hepatitis b e antigens hepatitis b surface antigens hepatitis b, chronic hepatitis b virus

StephenW

https://academic.oup.com/jid/adv ... 3222739/jiaa192.pdf